XML 32 R21.htm IDEA: XBRL DOCUMENT v3.26.3
Note 15 - Stock-based Compensation
9 Months Ended
Sep. 30, 2026
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]
Note 15. Stock-Based Compensation
 

2023 Equity Incentive Plan

 

In July 2023, the Company’s stockholders approved the 2023 Plan, which provided for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, performance-based stock awards and other forms of equity compensation to the Company’s employees, directors and consultants. Stock options granted under the 2023 Plan to employees and consultants generally will vest annually over a five-year period or as determined by the Board’s Compensation Committee (the "Committee"), while grants to non-employee directors vest as determined by the Committee. As of  September 30, 2026 and  December 31, 2025,  693,701 and  19,452 shares of common stock were reserved for issuance pursuant to future awards under the 2023 Plan. The number of shares available for issuance under the 2023 Plan also includes a quarterly increase commencing on September 1, 2023 by an amount equal to the lesser of (i) 10% of the number equal to the number of shares of common stock outstanding on the applicable adjustment date less the number of shares of common stock outstanding at the beginning of the fiscal quarter immediately preceding the adjustment date, but if such number is a negative number, then the increase will be zero; or (ii) such lesser number of shares as may be determined by the Board.
 
On September 30, 2026, at the Annual Meeting of Stockholders of the Company, the stockholders approved an amendment to the Company’s 2023 Equity Incentive Plan to increase the number of shares of the Company’s common stock reserved for issuance thereunder by 500,000 shares. The Board of Directors had previously approved the amendment, subject to stockholder approval.
 
At the Annual Meeting, the Company’s stockholders also approved a one-time repricing (the “Repricing”) of outstanding stock options with an exercise price greater than the fair market value of the Company’s common stock on the date of stockholder approval. As a result of the Repricing, the exercise price of the affected outstanding stock options was reduced to $1.52 per share, which represented the closing price of the Company’s common stock on the NYSE American on September 30, 2026. The Repricing did not modify the number of shares underlying the affected options, their expiration dates or their vesting schedules.

 

The Company accounted for the Repricing as a modification of the affected stock option awards pursuant to ASC Topic 718. The incremental fair value of the modified awards was measured as the excess of the fair value of the modified awards over the fair value of the original awards immediately prior to the modification. The Repricing resulted in incremental stock-based compensation cost of approximately $27 thousand, of which approximately $20 thousand was recognized during the three and nine months ended September 30, 2026. The remaining $7 thousand of unrecognized incremental compensation cost will be recognized over the remaining requisite service periods of the unvested modified awards.

 

 

For the nine months ended September 30, 2026. the Committee approved the grant of 20,000 stock options with service-based conditions. The options vest in equal installments over requisite service period of 180 days. No stock options with performance-based conditions were granted during the nine months ended September 30, 2026. 

 

The options granted for the 2023 Plan for the  nine months ended September 30, 2026 and 2025 were valued using the Black-Scholes model based on the following assumptions on the date of issue:
 
Options with Time-Based Vesting Conditions
  

For the Nine Months Ended

 
  

September 30,

 
  

2026

  

2025

 

Risk-free interest rate

  4.11%  4.29 - 4.55%

Volatility

  105.06   97.40 - 100%

Expected dividend yield

  0%  0%

Expected life (in years)

  5.5   5.5 - 6.5 

 

Options with Performance-Based Vesting Conditions

  

For the Nine Months Ended

 
  

September 30,

 
  

2026

  

2025

 

Risk-free interest rate

  —   4.55%

Volatility

  —   98.00 - 98.40%

Expected dividend yield

  —   0%

Expected life (in years)

  —   5.3 - 5.5 

 

 

The following is a summary of stock option activity for the 2023 Plan options for the nine months ended September 30, 2026:

 

      

Weighted

  

Weighted

     
      

Average

  

Average

  

Aggregate

 
  Stock  Exercise  Remaining  Intrinsic Value 
  

Options

  

Price

  

Life

  

(in thousands)

 

Outstanding at December 31, 2025

  12,368  $80.72   9.29  $— 

Options exercised

  —   —   —   — 

Options granted

  20,000   11.50   —   — 

Cancelled/forfeited

  (1,736)  98.63   —   — 

Outstanding at September 30, 2026

  30,632  $1.52   9.16  $— 

Vested and expected to vest at September 30, 2026

  30,632  $1.52   9.16  $— 

Exercisable at September 30, 2026

  23,798  $1.52   9.32  $— 

 

The weighted-average grant-date fair value of the 2023 Plan options granted during the nine months ended September 30, 2026 and 2025 was $3.99 and $44.06 per share, respectively.

 

Non-Plan Options Issued

 

On January 6, 2025, the Board approved and issued a total of 2,631 Non-Plan Options as an employee incentive to the Chief Financial Officer. The options vest monthly over 3 years with an exercise price of $1.52 and an expiration date of January 6, 2035.

 

For the nine months ended September 30, 2026 the Board approved and issued a total of 17,500 Non-Plan Options as an employee incentive to Marc Sellouk. The options vest 100% on grant date with an exercise price of $1.52 and an expiration date of April 1, 2036.

 

The Non-Plan Options issued for the nine months ended September 30, 2026 and 2025 were valued using the Black-Scholes model based on the following assumptions on the date of issue:

 

  

For the Nine Months Ended

 
  

September 30,

 
  

2026

  

2025

 

Risk-free interest rate

  4.33%  4.62%

Volatility

  105.31   97.00%

Expected dividend yield

  0%  0%

Expected life (in years)

  5.5   5.8 

 

The following is a summary of stock option activity for the Non-Plan options for the nine months ended September 30, 2026:

 

      

Weighted

  

Weighted

     
      

Average

  

Average

  

Aggregate

 
  Stock  Exercise  Remaining  Intrinsic Value 
  

Options

  

Price

  

Life

  

(in thousands)

 

Outstanding at December 31, 2025

  2,631  $100.70   9.02  $— 

Options exercised

  —   —   —   — 

Options granted

  17,500   11.50   —   — 

Cancelled/forfeited

  —   —   —   — 

Outstanding at September 30, 2026

  20,131  $1.52   9.35  $— 

Vested and expected to vest at September 30, 2026

  20,131  $1.52   9.35  $— 

Exercisable at September 30, 2026

  18,961  $1.52   9.41  $— 

 

The weighted-average grant-date fair value of the Non-Plan options granted during the nine months ended September 30, 2026 and 2025 was $3.70 and $79.21 per share, respectively.

 

Stock-based compensation expense is recorded in selling, general and administrative expenses in the condensed consolidated statements of operations. Stock-based compensation expense for the three and nine months ended September 30, 2026 was $161 thousand and $491 thousand, respectively, which includes $20 thousand of incremental stock-based compensation expense recognized in connection with the Repricing described above. Stock-based compensation for the three and nine months ended September 30, 2025 was $70 thousand and $259 thousand, respectively. 

 

Total unrecognized estimated stock-based compensation expense by award type and the remaining weighted average recognition period over which such expense is expected to be recognized at  September 30, 2026 was as follows:

 

  

Unrecognized Expense (in thousands)

  

Remaining Weighted Average Recognition Period

 

Stock options (Non-Plan Options)

 $140   0.01 

Stock options (2023 Plan Options)

 $228   2.91